This event is part of Friends of Europe’s Health and Wellbeing programme, which focuses on how the obstacles of vested interests and short-term political thinking can be overcome in the difficult transition to new healthcare models and systems – and how these new systems can be financed.
Should you not be able to view the photo gallery, please click here.
- Event summary
- Three things Europe can do in the fight against AMR, by Xavier Prats Monné, European Commission Director-General for Health
- Antimicrobial resistance is a global threat that needs global action – now, by Francesca Colombo, Head of the OECD Health Division
- EFPIA, EBE and Vaccines Europe Back EU Leadership in Sustainable, Collaborative Fight Against AMR
Join the conversation on our Twitter using #FoEDebate
IMAGE CREDIT: Bigstock – SiriratM / famveldman / RGtimeline
Demographic shifts, greater demand and the prolonged economic crisis are putting European health systems under extreme pressure.
We look at how the obstacles of vested interests and short-term political thinking can be overcome in the difficult transition to new healthcare models and systems – and how these new systems can be financed.
12.30 - 13.00
Welcome lunch and registration of participants
Antimicrobial resistance (AMR) is a growing global health emergency that threatens to undermine the medical progress of the past century. 50,000 people die every year in the European Union and the United States from antimicrobial resistant infections. The Review on Antimicrobial Resistance chaired by Jim O’Neill projected that if AMR cannot be addressed by 2050, ten million people would die each year, combined with a reduction in global GDP of 2% to 3.5% and a total cost of 100 trillion dollars.
The EU has coordinated efforts to curb misuse of antibiotics, but in 2015 resistance to last-line antibiotics continued to increase. In parts of Europe, there are patients in intensive care, haematology and transplant units with infections for which there is no effective treatment available. Some member states have managed to reduce antibiotic use in hospitals, but antibiotic consumption increased in others.
The ‘One Health Action Plan’ adopted by the European Commission in June 2017 provides a scope for EU action against AMR, but much still needs to be done to establish the EU as a global leader in the field. To shape the global agenda, the EU will need to deliver on its commitments and act within its mandate to add value to member states’ actions.
- What are the scientific challenges to developing new antibiotics?
- How could the EU remove the roadblocks to innovation and accelerate progress to manage antibiotics better?
- Given the important relationship for AMR between trade, animals in agriculture and human health, how can all relevant EU departments and agencies be mobilised to tackle AMR?
- How do we change cultural expectations so there is less demand for antibiotics, fewer prescriptions by doctors and greater adherence by patients?
Cristian-Silviu Busoi, Member of the European Parliament Committee on Industry, Research and Energy
Francesca Colombo, Head of the OECD Health Division
Jean Lang, Associate Vice President at Sanofi Pasteur Research & Development
Wolfgang Philipp, Head of Unit Crisis management and preparedness in health, European Commission Directorate General for Health and Food Safety
End of debate
In association with
Tel. +32 2 893 98 23
This event is exclusively for Friends of Europe’s members, EU institution representatives and media.